Adam JacksonCanadian cannabis producer Organigram Holdings (NASDAQ: OGI) (TSX: OGI) took steps toward European expansion with a €14 million (approximately C$21 million) investment in German cannabis company Sanity Group GmbH, the company announced Tuesday.
The investment is funded through Organigram’s Jupiter strategic investment pool and consists of an €11.5 million unsecured convertible note, as well as a €2.5 million equity stake. That gives Organigram a minority position in the Berlin-based firm and the right to appoint a representative to Sanity Group’s board of directors.
“A meaningful presence in Germany and Europe are essential to achieving our ambitions to be a global cannabis leader,” Organigram CEO Beena Goldenberg said in a statement. The company views Germany as a promising market, second only to Canada in potential for nationally legal cannabis.
The deal also expands an existing supply agreement between the two companies. Sanity Group committed to purchasing significantly higher volumes of dried flower from Organigram, with plans to shift to a percentage-based commitment once Organigram receives EU-GMP certification for its Moncton, New Brunswick, facility.
Sanity Group, founded in 2018, quickly established itself as a leader in the German cannabis market. The company claims approximately 10% market share in German medical cannabis, with its medical brand estimated to hold the second position in the market.
Germany’s cannabis industry is poised for significant growth following recreational cannabis legal reforms enacted earlier this year. According to estimates from cannabis market research firm BDSA cited by Organigram, Germany is expected to generate approximately $1.5 billion in total cannabis sales in 2024, growing to $3.7 billion by 2027.
The investment in Sanity Group marks Organigram’s first significant strategic move to expand its European presence. It follows a trend of North American cannabis companies seeking to establish footholds in the emerging European market.
